{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T00:48:11Z","timestamp":1772930891819,"version":"3.50.1"},"reference-count":27,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,8,30]],"date-time":"2022-08-30T00:00:00Z","timestamp":1661817600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Autologous stem cell transplantation (ASCT) remains the standard of care for patients with newly diagnosed multiple myeloma (MM). Several attempts to improve the efficacy of conditioning regimens have been conducted in MM, but no more effective regimen than conventional high-dose melphalan has been introduced.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>In this study, the efficacy and toxicity of busulfan and thiotepa (BuTT) and those of high-dose melphalan (HD-MEL) were compared retrospectively as a conditioning regimen for ASCT in patients with MM.<\/jats:p><\/jats:sec><jats:sec><jats:title>Study design<\/jats:title><jats:p>Included in the analysis were 114 patients who received BuTT and 114 patients who received HD-MEL treatment between March 2008 and May 2020. The BuTT regimen consisted of intravenous thiotepa 5 mg\/kg once a day from days 7 to 6, followed by intravenous busulfan 3.2 mg\/kg once a day from days 5 to 3. The HD-MEL conditioning regimen consisted of melphalan 100 mg\/m<jats:sup>2<\/jats:sup> once a day from days 3 to 2.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The overall response rate after ASCT did not differ between BuTT and HD-MEL (94.7% in BuTT vs. 97.4% in HD-MEL, <jats:italic>p<\/jats:italic> = 0.333). After a median follow-up of 47.6 months, progression-free survival (PFS) tended to be longer in the BuTT group (median PFS, 41.5 months vs. 30.3 months; hazard ratio (HR), 0.706; 95% confidence interval (CI), 0.497\u20131.004, <jats:italic>p<\/jats:italic> = 0.053). In the subgroup analysis of patients who did not proceed to maintenance or consolidation treatment after ASCT, the difference in PFS became more significant (median PFS, 41.5 months vs. 24.4 months; HR, 0.621; 95% CI, 0.388\u20130.993; <jats:italic>p<\/jats:italic> = 0.047). Additionally, the BuTT group had fewer adverse events, such as grade 3 or 4 stomatitis and diarrhea, than the HD-MEL group (stomatitis, 10.5% vs. 23.7%, <jats:italic>p<\/jats:italic> = 0.013; diarrhea, 10.5% vs. 25.4%, <jats:italic>p<\/jats:italic> = 0.005). There was no difference in the occurrence of venous-occlusive disease (2.6% in BuTT vs. 0.9% in HD-MEL, <jats:italic>p<\/jats:italic> = 0.622).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Our study results suggest that BuTT is an effective alternative conditioning regimen with reduced toxicity in patients with newly diagnosed MM.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2022.959949","type":"journal-article","created":{"date-parts":[[2022,8,30]],"date-time":"2022-08-30T04:52:47Z","timestamp":1661835167000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["Busulfan and thiotepa as a conditioning regimen for autologous stem cell transplantation in patients with multiple myeloma: A study of the Korean Multiple Myeloma Working Party (KMMWP-1801 study)"],"prefix":"10.3389","volume":"12","author":[{"given":"Ga-Young","family":"Song","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sung-Hoon","family":"Jung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin Seok","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyeon Seok","family":"Eom","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joon Ho","family":"Moon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ho-Young","family":"Yhim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kihyun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chang-Ki","family":"Min","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Je-Jung","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,8,30]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-10-299529","article-title":"Consensus recommendations for standard investigative workup: report of the international myeloma workshop consensus panel 3","volume":"117","author":"Dimopoulos","year":"2011","journal-title":"Blood"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2017.181339","article-title":"Melphalan 140 mg\/m(2) or 200 mg\/m(2) for autologous transplantation in myeloma: results from the collaboration to collect autologous transplant outcomes in lymphoma and myeloma (CALM) study. a report by the EBMT chronic malignancies working party","volume":"103","author":"Auner","year":"2018","journal-title":"Haematologica"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-018-0379-y","article-title":"Melphalan dose in myeloma patients \u226565 years of age undergoing high-dose therapy and autologous stem cell transplantation: a multicentric observational registry study","volume":"54","author":"Ghilardi","year":"2019","journal-title":"Bone Marrow Transplantation"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2016.150334","article-title":"Upfront autologous stem cell transplantation for newly diagnosed elderly multiple myeloma patients: a prospective multicenter study","volume":"101","author":"Garderet","year":"2016","journal-title":"Haematologica"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2016.174","article-title":"Autologous stem cell transplant for multiple myeloma patients 70 years or older","volume":"51","author":"Muchtar","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1703917","article-title":"High-dose thiotepa, busulfan, cyclophosphamide and ASCT without whole-brain radiotherapy for poor prognosis primary CNS lymphoma","volume":"31","author":"Cheng","year":"2003","journal-title":"Bone Marrow Transplantation"},{"key":"B7","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.bbmt.2011.07.006","article-title":"Autologous stem cell transplantation with thiotepa, busulfan, and cyclophosphamide (TBC) conditioning in patients with CNS involvement by non-Hodgkin lymphoma","volume":"18","author":"Cote","year":"2012","journal-title":"Biol Blood Marrow Transplantation"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.3.742","article-title":"Results of intensive chemotherapy followed by hematopoietic stem-cell rescue in 22 patients with refractory or recurrent primary CNS lymphoma or intraocular lymphoma","volume":"19","author":"Soussain","year":"2001","journal-title":"J Clin Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.20294","article-title":"Comparison of high-dose melphalan with a more intensive regimen of thiotepa, busulfan, and cyclophosphamide for patients with multiple myeloma","volume":"100","author":"Anagnostopoulos","year":"2004","journal-title":"Cancer"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V82.8.2324.bloodjournal8282324","article-title":"Thiotepa, busulfan, and cyclophosphamide: A new preparative regimen for autologous marrow or blood stem cell transplantation in high-risk multiple myeloma","volume":"82","author":"Dimopoulos","year":"1993","journal-title":"Blood"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1703007","article-title":"Thiotepa, busulfan, cyclophosphamide (TBC) and autologous hematopoietic transplantation: an intensive regimen for the treatment of multiple myeloma","volume":"27","author":"Shimoni","year":"2001","journal-title":"Bone Marrow Transplant"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.61.2267","article-title":"Revised international staging system for multiple myeloma: A report from international myeloma working group","volume":"33","author":"Palumbo","year":"2015","journal-title":"J Clin Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International myeloma working group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-198712000-00011","article-title":"Venoocclusive disease of the liver following bone marrow transplantation","volume":"44","author":"Jones","year":"1987","journal-title":"Transplantation"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-118-4-199302150-00003","article-title":"Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients","volume":"118","author":"McDonald","year":"1993","journal-title":"Ann Internal Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2012.08.011","article-title":"Fifty years of melphalan use in hematopoietic stem cell transplantation","volume":"19","author":"Bayraktar","year":"2013","journal-title":"Biol Blood Marrow Transplantation"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1080\/16078454.2022.2059630","article-title":"High dose melphalan is an adequate preparative regimen for autologous hematopoietic stem cell transplantation in relapsed\/refractory lymphoma","volume":"27","author":"Fern\u00e1ndez-Guti\u00e9rrez","year":"2022","journal-title":"Hematol (Amsterdam Netherlands)"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(195301)6:1<142::AID-CNCR2820060114>3.0.CO;2-W","article-title":"Clinical studies on triethylenephosphoramide and diethylenephosphoramide, compounds with nitrogen-mustard-like activity","volume":"6","author":"Sykes","year":"1953","journal-title":"Cancer"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1965.58","article-title":"Thiotepa in the treatment of advanced breast cancer","volume":"19","author":"Lyons","year":"1965","journal-title":"Br J Cancer"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1053\/ctrv.2000.0170","article-title":"Chemistry, pharmacology and pharmacokinetics of N,N',N\" -triethylenethiophosphoramide (ThioTEPA)","volume":"26","author":"Maanen","year":"2000","journal-title":"Cancer Treat Rev"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2013.782608","article-title":"Autologous transplant in multiple myeloma with an augmented conditioning protocol","volume":"54","author":"Abu Zaid","year":"2013","journal-title":"Leuk Lymphoma"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(19)30023-7","article-title":"Conditioning with busulfan plus melphalan versus melphalan alone before autologous haemopoietic cell transplantation for multiple myeloma: an open-label, randomised, phase 3 trial","volume":"6","author":"Bashir","year":"2019","journal-title":"Lancet Haematology"},{"key":"B23","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.bbmt.2012.08.009","article-title":"Intravenous busulfan and melphalan as a conditioning regimen for autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: a matched comparison to a melphalan-only approach","volume":"19","author":"Blanes","year":"2013","journal-title":"Biol Blood marrow Transplant J Am Soc Blood Marrow Transplantation"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1038\/sj.thj.6200369","article-title":"Melphalan versus melphalan plus busulphan in conditioning to autologous stem cell transplantation for low-risk multiple myeloma","volume":"5","author":"Ria","year":"2004","journal-title":"Hematol J Off J Eur Haematology Assoc"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2020.1783448","article-title":"Intravenous busulfan and melphalan versus high-dose melphalan as a conditioning regimen for early autologous stem cell transplantation in patients with multiple myeloma: a propensity score-matched analysis","volume":"61","author":"Song","year":"2020","journal-title":"Leukemia Lymphoma"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2015.06.011","article-title":"High-dose melphalan plus thiotepa as conditioning regimen before second autologous stem cell transplantation for \u201cDe\u00a0Novo\u201d multiple myeloma patients: A phase II study","volume":"21","author":"Musso","year":"2015","journal-title":"Biol Blood Marrow Transplantation"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2012-0384","article-title":"Efficacy and safety of busulfan-based conditioning regimens for multiple myeloma","volume":"18","author":"Reece","year":"2013","journal-title":"Oncologist"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.959949\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,30]],"date-time":"2022-08-30T04:52:50Z","timestamp":1661835170000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.959949\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,30]]},"references-count":27,"alternative-id":["10.3389\/fonc.2022.959949"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2022.959949","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,30]]},"article-number":"959949"}}